MatTek and AIM Biotech Companion on Superior 3D Tissue Tradition Organ-on-a-Chip Techniques


As we speak, MatTek Life Sciences and AIM Biotech introduced a strategic partnership by which the AIM Biotech portfolio will probably be accessible on the market by MatTek. Over the past thirty years, MatTek has grow to be the chief within the superior cell tradition house and is regularly working to broaden its portfolio of services and products. The partnership with AIM Biotech permits MatTek to supply an ever extra complete suite of services and products to its shoppers and prospects.

This contains the revolutionary organiX™ and idenTX™ microfluidic 3D tissue tradition platforms in addition to complete drug discovery analysis companies in key therapeutic areas of immuno-oncology, vascular biology, and neurobiology.

Whereas MatTek has led the sector in superior cell tradition and tissue tradition for many years with fashions resembling EpiDerm™, and most just lately EpiKidney™, these fashions have been developed as a single organ system inside an in vitro format. As researchers push the envelope on superior in vitro methods, they’re changing into extra thinking about fashions which incorporate much more physiologically related options, resembling perfusable vasculature, and even combining a number of organ methods.

Considered one of our targets is to proceed to reinforce the complexity of in vitro tissue know-how and hold bringing it nearer and nearer to in vivo human biology, and the microfluidic cell tradition platforms from AIM Biotech can just do that,” mentioned MatTek CEO Alex Armento. “By partnering with AIM Biotech we are able to extra simply add perfusable vasculature to in vitro fashions and construct ever extra physiologically related assays which assist higher predict in vivo outcomes.”

“AIM Biotech is worked up to accomplice with MatTek in an effort to get our superior 3D tissue tradition platforms in addition to our in depth portfolio of application-specific steerage and companies into the fingers of extra researchers from world wide. Collectively we’re taking the initiative to mix AIM Biotech’s skill to create self-assembling, immunocompetent, perfusable methods with MatTek’s extensively validated cell tradition fashions. This may allow us to advance the event of assay-ready methods that are simpler to make use of and can present physiological information earlier within the drug growth course of,” described AIM Biotech CEO Jim McGorry.

AIM Biotech’s Organ-on-a-Chip Tissue Tradition Platforms at the moment are accessible on the market on MatTek’s on-line retailer.